Bright Minds Biosciences
DRUG
94 hedge funds and large institutions have $670M invested in Bright Minds Biosciences in 2026 Q1 according to their latest regulatory filings, with 29 funds opening new positions, 45 increasing their positions, 15 reducing their positions, and 7 closing their positions.
314% more first-time investments, than exits
New positions opened: 29 | Existing positions closed: 7
200% more repeat investments, than reductions
Existing positions increased: 45 | Existing positions reduced: 15
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
30% more capital invested
Capital invested by funds: $515M → $670M (+$155M)
27% more funds holding
Funds holding: 74 → 94 (+20)
9.77% more ownership
Funds ownership: 84.64% → 94.41% (+9.8%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VPC
Vestal Point Capital
New York
|
+$39.6M |
| 2 |
DM
Deerfield Management
New York
|
+$22.8M |
| 3 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$21.3M |
| 4 |
BlackRock
New York
|
+$18.3M |
| 5 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$17.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$11.4M |
| 2 |
SC
Stempoint Capital
New York
|
-$7.6M |
| 3 |
PA
Perceptive Advisors
New York
|
-$5.78M |
| 4 |
SCM
Superstring Capital Management
New York
|
-$2.73M |
| 5 |
BNP Paribas Financial Markets
Paris,
France
|
-$1.94M |
DRUG Hedge Fund Activity: Q1 2026 in Review
94 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in Bright Minds Biosciences (DRUG) for Q1 2026, worth a combined $670M — up 30% from $515M a quarter earlier.
Buyers outnumbered sellers: 29 funds opened new DRUG positions and 7 closed out — a net gain of 22 holders — while 45 added to existing stakes and 15 trimmed.
The largest buyer was Vestal Point Capital, opening a new position worth an estimated $39.6M. The largest seller was Millennium Management, cutting an estimated $11.4M.
- 94 institutional investors held Bright Minds Biosciences (DRUG) as of Q1 2026, up from 74 in Q4 2025.
- Funds reported $670M of Bright Minds Biosciences stock for Q1 2026, up 30% quarter-over-quarter.
- 29 funds opened new Bright Minds Biosciences positions in Q1 2026 and 7 closed out, a net change of +22 holders.
- The largest Bright Minds Biosciences buyer in Q1 2026 was Vestal Point Capital, an estimated $39.6M added.
- The largest Bright Minds Biosciences seller in Q1 2026 was Millennium Management, an estimated $11.4M sold.
Based on aggregated 13F filings for Q1 2026.